{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:39:08Z","timestamp":1793093948963,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GD Goenka University","award":["R&D10\/24\/03"],"award-info":[{"award-number":["R&D10\/24\/03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-03931-0","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:09:39Z","timestamp":1768986579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation"],"prefix":"10.1007","volume":"46","author":[{"given":"Monika","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Monika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Jhawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"3931_CR1","unstructured":"National Eye Institute. (2016, March 29). Facts about glaucoma. https:\/\/www.nei.nih.gov\/health\/glaucoma\/glaucoma_facts"},{"key":"3931_CR2","unstructured":"American Academy of Ophthalmology. (2022, December 6). What is glaucoma? Symptoms, causes, diagnosis, treatment. https:\/\/www.aao.org\/eye-health\/diseases\/what-is-glaucoma"},{"issue":"11","key":"3931_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11):2081\u20132090. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013","journal-title":"Ophthalmology"},{"key":"3931_CR4","doi-asserted-by":"publisher","unstructured":"Bourne RRA, Steinmetz JD, Flaxman S, Briant PS, Taylor HR, Resnikoff S, GBD 2020 Blindness and Vision Impairment Collaborators (2024) Global estimates on the number of people blind or visually impaired due to glaucoma. Eye 38(1):188\u2013200. https:\/\/doi.org\/10.1038\/s41433-024-02995-5","DOI":"10.1038\/s41433-024-02995-5"},{"issue":"2","key":"3931_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14740338.2024.2436062","volume":"24","author":"G Holl\u00f3","year":"2025","unstructured":"Holl\u00f3 G (2025) Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opin Drug Saf 24(2):145\u2013156. https:\/\/doi.org\/10.1080\/14740338.2024.2436062","journal-title":"Expert Opin Drug Saf"},{"key":"3931_CR6","unstructured":"Chang E, Sarrafpour S, Teng CC (2021, January\u2013February). Side effects of glaucoma medications. Glaucoma Today"},{"key":"3931_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6138132","volume":"2020","author":"B Cvenkel","year":"2020","unstructured":"Cvenkel B, Kolko M (2020) Current medical therapy and future trends in glaucoma management. J Ophthalmol 2020:6138132. https:\/\/doi.org\/10.1155\/2020\/6138132","journal-title":"J Ophthalmol"},{"key":"3931_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/CIA.S132454","volume":"12","author":"JW Kwon","year":"2017","unstructured":"Kwon JW, Han SB (2017) Omega-3 fatty acid supplementation can improve both symptoms and signs of dry eye disease. Clin Interv Aging 12:485\u2013486. https:\/\/doi.org\/10.2147\/CIA.S132454","journal-title":"Clin Interv Aging"},{"issue":"2","key":"3931_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtos.2019.11.004","volume":"17","author":"LE Downie","year":"2019","unstructured":"Downie LE, Hom MM, Berdy GJ, El-Harazi S, Verachtert A, Tan J, Liu H, Carlisle-Wilcox C, Simmons P, Vehige J (2019) An artificial tear containing flaxseed oil for treating dry eye disease: a randomized controlled trial. Ocul Surf 17(2):299\u2013308. https:\/\/doi.org\/10.1016\/j.jtos.2019.11.004","journal-title":"Ocul Surf"},{"issue":"5","key":"3931_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/ICO.0000000000001884","volume":"38","author":"G Giannaccare","year":"2019","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S, Bernabei F, Roda M, Taroni L, Versura P, Campos EC (2019) Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea 38(5):565\u2013573. https:\/\/doi.org\/10.1097\/ICO.0000000000001884","journal-title":"Cornea"},{"issue":"1","key":"3931_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81983-1","volume":"11","author":"DJ Kim","year":"2021","unstructured":"Kim DJ, Jung MY, Pak HJ, Kim N, Park HY, Kim HJ, Shin JH (2021) Development of a novel hyaluronic acid membrane for the treatment of ocular surface diseases. Sci Rep 11(1):2351. https:\/\/doi.org\/10.1038\/s41598-021-81983-1","journal-title":"Sci Rep"},{"key":"3931_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118006","volume":"264","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wei D, Xu Y, Zhu Q (2021) Hyaluronic acid in ocular drug delivery. Carbohydr Polym 264:118006. https:\/\/doi.org\/10.1016\/j.carbpol.2021.118006","journal-title":"Carbohydr Polym"},{"issue":"9","key":"3931_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26092485","volume":"26","author":"WH Chang","year":"2021","unstructured":"Chang WH, Liu PY, Lin MH, Lu CJ, Chou HY, Nian CY, Jiang YT, Hsu YH (2021) Applications of hyaluronic acid in ophthalmology and contact lenses. Molecules 26(9):2485. https:\/\/doi.org\/10.3390\/molecules26092485","journal-title":"Molecules"},{"issue":"4","key":"3931_CR14","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.4.13","volume":"12","author":"L Nguyen","year":"2023","unstructured":"Nguyen L, Lin X, Verma S, Puri S, Hascall V, Gesteira TF, Coulson-Thomas VJ (2023) Characterization of the molecular weight of hyaluronan in eye products using a novel method of size exclusion high-pressure liquid chromatography. Transl Vis Sci Technol 12(4):13. https:\/\/doi.org\/10.1167\/tvst.12.4.13","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"3931_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","volume":"2","author":"A Patel","year":"2013","unstructured":"Patel A, Cholkar K, Agrahari V, Mitra AK (2013) Ocular drug delivery systems: an overview. World J Pharmacol 2(2):47\u201364. https:\/\/doi.org\/10.5497\/wjp.v2.i2.47","journal-title":"World J Pharmacol"},{"issue":"21","key":"3931_CR16","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.2174\/138161209788923886","volume":"15","author":"S Wadhwa","year":"2009","unstructured":"Wadhwa S, Paliwal R, Paliwal SR, Vyas SP (2009) Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des 15(21):2724\u20132750. https:\/\/doi.org\/10.2174\/138161209788923886","journal-title":"Curr Pharm Des"},{"issue":"4","key":"3931_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/jop.2004.20.317","volume":"20","author":"FT Fraunfelder","year":"2004","unstructured":"Fraunfelder FT, Meyer SM, Paredes A (2004) Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol Ther 20(4):317\u2013326. https:\/\/doi.org\/10.1089\/jop.2004.20.317","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"3931_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067010","volume":"95","author":"TJ Zimmerman","year":"1977","unstructured":"Zimmerman TJ, Kaufman HE (1977) Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95(4):601\u2013604. https:\/\/doi.org\/10.1001\/archopht.1977.04450040067010","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"3931_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0002-9394(99)00011-2","volume":"127","author":"A Konowal","year":"1999","unstructured":"Konowal A, Morrison JC, Brown SVL, Crowe S, Budenz DL, Herndon L, Kaufman HE (1999) Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 127(4):403\u2013406. https:\/\/doi.org\/10.1016\/S0002-9394(99)00011-2","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3931_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archopht.1997.01100190705029","volume":"115","author":"JS Schuman","year":"1997","unstructured":"Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K (1997) A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol 115(7):847\u2013852. https:\/\/doi.org\/10.1001\/archopht.1997.01100190705029","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"3931_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0002-9394(99)00003-3","volume":"127","author":"LJ Katz","year":"1999","unstructured":"Katz LJ (1999) Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol 127(1):20\u201326. https:\/\/doi.org\/10.1016\/S0002-9394(99)00003-3","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3931_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT (2005) Management of glaucoma: focus on pharmacological therapy. Drugs Aging 22(1):1\u201321. https:\/\/doi.org\/10.2165\/00002512-200522010-00001","journal-title":"Drugs Aging"},{"key":"3931_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2018.03.018","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, Ramirez-Davis N, Usner DW, Kopczynski CC, Heah T (2018) Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol 186:116\u2013127. https:\/\/doi.org\/10.1016\/j.ajo.2018.03.018","journal-title":"Am J Ophthalmol"},{"key":"3931_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.02.001","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, Wirostko B, Shapiro D, Tressler C, Heah T (2019) Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho kinase elevated IOP treatment trial 3 (ROCKET-3). Am J Ophthalmol 200:130\u2013137. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.001","journal-title":"Am J Ophthalmol"},{"key":"3931_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.012","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Heah T (2019) Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol 204:97\u2013104. https:\/\/doi.org\/10.1016\/j.ajo.2019.03.012","journal-title":"Am J Ophthalmol"},{"key":"3931_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","volume":"207","author":"S Asrani","year":"2019","unstructured":"Asrani S, Robin AL, Serle JB, Lewis RA, Usner D, Kopczynski C, Heah T (2019) Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol 207:248\u2013257. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3931_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","volume":"36","author":"MH Goldstein","year":"2022","unstructured":"Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S (2022) Ocular exposure to benzalkonium chloride: problems and solutions. Eye (Lond) 36(2):361\u2013368. https:\/\/doi.org\/10.1038\/s41433-021-01668-x","journal-title":"Eye (Lond)"},{"issue":"7","key":"3931_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040893","volume":"7","author":"W Chen","year":"2012","unstructured":"Chen W, Hu J, Zhang Z, Chen L, Xie H, Dong N, Chen Y, Liu Z (2012) Localization and expression of zonula occludins-1 in the rabbit corneal epithelium following exposure to benzalkonium chloride. PLoS ONE 7(7):e40893. https:\/\/doi.org\/10.1371\/journal.pone.0040893","journal-title":"PLoS ONE"},{"issue":"11","key":"3931_CR29","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.14.11.16","volume":"14","author":"X Zheng","year":"2025","unstructured":"Zheng X, Shawky M, Ogando DG, Nishiyama M, Ibrahim AS, Srinivas SP (2025) Effects of benzalkonium chloride, a preservative in topical drugs, on the barrier function of human corneal epithelial cells. Transl Vis Sci Technol 14(11):16. https:\/\/doi.org\/10.1167\/tvst.14.11.16","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"3931_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/toxics8010017","volume":"8","author":"SH Kim","year":"2020","unstructured":"Kim SH, Kwon D, Lee S, Son SW, Kwon JT, Kim PJ, Lee YH, Jung YS (2020) Concentration- and time-dependent effects of benzalkonium chloride in human lung epithelial cells: necrosis, apoptosis, or epithelial mesenchymal transition. Toxics 8(1):17. https:\/\/doi.org\/10.3390\/toxics8010017","journal-title":"Toxics"},{"issue":"7","key":"3931_CR31","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1111\/aos.14410","volume":"98","author":"C Chamard","year":"2020","unstructured":"Chamard C, Larrieu S, Baudouin C, Bron A, Villain M, Daien V (2020) Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmol 98(7):e876\u2013e881. https:\/\/doi.org\/10.1111\/aos.14410","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"3931_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","volume":"97","author":"DG Day","year":"2013","unstructured":"Day DG, Walters TR, Schwartz GF, Mundorf TK, Liu C, Schiffman RM, Bejanian M (2013) Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol 97(8):989\u2013993. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-303040","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"3931_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1442-9071.2000.00237.x","volume":"28","author":"MK Arici","year":"2000","unstructured":"Arici MK, Arici DS, Topalkara A, G\u00fcler C (2000) Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol 28(2):113\u2013117. https:\/\/doi.org\/10.1046\/j.1442-9071.2000.00237.x","journal-title":"Clin Exp Ophthalmol"},{"key":"3931_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/165475","volume":"2015","author":"W Zhu","year":"2015","unstructured":"Zhu W, Kong X, Xu J, Sun X (2015) Effects of long-term antiglaucoma eye drops on conjunctival structures: an in vivo confocal microscopy study. J Ophthalmol 2015:Article 165475. https:\/\/doi.org\/10.1155\/2015\/165475","journal-title":"J Ophthalmol"},{"issue":"3","key":"3931_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","volume":"16","author":"ABC Wong","year":"2018","unstructured":"Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP (2018) Exploring topical antiglaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf 16(3):289\u2013293. https:\/\/doi.org\/10.1016\/j.jtos.2018.03.002","journal-title":"Ocul Surf"},{"issue":"3","key":"3931_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1600-0420.1995.tb00277.x","volume":"73","author":"IS Yalva\u00e7","year":"1995","unstructured":"Yalva\u00e7 IS, Gediko\u011flu G, Karag\u00f6z Y, Akg\u00fcn U, Nur\u00f6zler A, Ko\u00e7 F, Kasim R, Duman S (1995) Effects of antiglaucoma drugs on the ocular surface. Acta Ophthalmol Scand 73(3):246\u2013248. https:\/\/doi.org\/10.1111\/j.1600-0420.1995.tb00277.x","journal-title":"Acta Ophthalmol Scand"},{"key":"3931_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.exer.2017.06.009","volume":"163","author":"MV Jeyalatha","year":"2017","unstructured":"Jeyalatha MV, Qu Y, Liu Z, Ou S, He X, Bu J, Li S, Reinach PS, Liu Z, Li W (2017) Function of the meibomian gland: contribution of proteins. Exp Eye Res 163:29\u201336. https:\/\/doi.org\/10.1016\/j.exer.2017.06.009","journal-title":"Exp Eye Res"},{"issue":"11","key":"3931_CR38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1097\/ICO.0b013e31823f8e7d","volume":"31","author":"R Arita","year":"2012","unstructured":"Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, Aihara M, Amano S (2012) Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea 31(11):1229\u20131234. https:\/\/doi.org\/10.1097\/ICO.0b013e31823f8e7d","journal-title":"Cornea"},{"issue":"3","key":"3931_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0002-9394(14)76730-3","volume":"112","author":"JD Brandt","year":"1991","unstructured":"Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL (1991) Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 112(3):297\u2013301. https:\/\/doi.org\/10.1016\/s0002-9394(14)76730-3","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3931_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0161-6420(89)32368-8","volume":"96","author":"MB Sherwood","year":"1989","unstructured":"Sherwood MB, Grierson I, Millar L, Hitchings RA (1989) Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon\u2019s capsule in glaucomatous patients. Ophthalmology 96(3):327\u2013335. https:\/\/doi.org\/10.1016\/s0161-6420(89)32368-8","journal-title":"Ophthalmology"},{"issue":"6","key":"3931_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3980\/j.issn.2222-3959.2013.06.13","volume":"6","author":"R Bhargava","year":"2013","unstructured":"Bhargava R, Kumar P, Kumar M, Mehra N, Mishra A (2013) A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol 6(6):811\u2013816. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2013.06.13","journal-title":"Int J Ophthalmol"},{"issue":"9","key":"3931_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3109\/02713683.2014.884595","volume":"39","author":"Z Li","year":"2014","unstructured":"Li Z, Choi JH, Oh HJ, Park SH, Lee JB, Yoon KC (2014) Effects of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye. Curr Eye Res 39(9):871\u2013878. https:\/\/doi.org\/10.3109\/02713683.2014.884595","journal-title":"Curr Eye Res"},{"key":"3931_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jtos.2023.11.005","volume":"31","author":"LE Downie","year":"2024","unstructured":"Downie LE, Ng SM, Craig JP (2024) Topical omega-3 for glaucoma-related dry eye: a randomized trial. Ocul Surf 31:102\u2013110. https:\/\/doi.org\/10.1016\/j.jtos.2023.11.005","journal-title":"Ocul Surf"},{"issue":"8","key":"3931_CR44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/aos.15159","volume":"100","author":"L Hynnekleiv","year":"2022","unstructured":"Hynnekleiv L, Magno M, Vernhardsdottir RR, Moschowits E, T\u00f8nseth KA, Dartt DA, Vehof J, Utheim TP (2022) Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol 100(8):844\u2013860. https:\/\/doi.org\/10.1111\/aos.15159","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"3931_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052383","volume":"18","author":"Y-J Yang","year":"2021","unstructured":"Yang Y-J, Lee W-Y, Kim Y-J, Hong Y-P (2021) A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome. Int J Environ Res Public Health 18(5):Article 2383. https:\/\/doi.org\/10.3390\/ijerph18052383","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"3931_CR46","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/aos.15159","volume":"100","author":"L Hynnekleiv","year":"2022","unstructured":"Hynnekleiv L, Magno M, Vernhardsdottir RR, Moschowits E, T\u00f8nseth KA, Dartt DA, Vehof J, Utheim TP (2022) Hyaluronic acid versus alternative lubricants in glaucoma-induced dry eye: RCT results. Acta Ophthalmol 100(8):844\u2013860. https:\/\/doi.org\/10.1111\/aos.15159","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"3931_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1167\/iovs.66.2.145","volume":"66","author":"DD Nguyen","year":"2025","unstructured":"Nguyen DD, Luo LJ, Yang CJ, Lai JY (2025) Hyaluronan nanocarriers for ocular surface regeneration in glaucoma therapy. Invest Ophthalmol Vis Sci 66(2):145\u2013152. https:\/\/doi.org\/10.1167\/iovs.66.2.145","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3931_CR48","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1021\/acsnano.2c05824","volume":"17","author":"DD Nguyen","year":"2023","unstructured":"Nguyen DD, Luo LJ, Yang CJ, Lai JY (2023) Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration. ACS Nano 17(1):168\u2013183. https:\/\/doi.org\/10.1021\/acsnano.2c05824","journal-title":"ACS Nano"},{"issue":"11","key":"3931_CR49","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.7150\/thno.54525","volume":"11","author":"LJ Luo","year":"2021","unstructured":"Luo LJ, Nguyen DD, Lai JY (2021) Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension. Theranostics 11(11):5447\u20135463. https:\/\/doi.org\/10.7150\/thno.54525","journal-title":"Theranostics"},{"key":"3931_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119961","volume":"243","author":"LJ Luo","year":"2020","unstructured":"Luo LJ, Nguyen DD, Lai JY (2020) Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: a push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy. Biomaterials 243:Article 119961. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119961","journal-title":"Biomaterials"},{"issue":"1","key":"3931_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2022.138620","volume":"451","author":"DD Nguyen","year":"2023","unstructured":"Nguyen DD, Yao C-H, Lue SJ, Yang C-J, Su Y-H, Huang C-C, Lai J-Y (2023) Amination-mediated nano eye-drops with enhanced corneal permeability and effective burst release for acute glaucoma treatment. Chem Eng J 451(1):Article 138620. https:\/\/doi.org\/10.1016\/j.cej.2022.138620","journal-title":"Chem Eng J"},{"issue":"26","key":"3931_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302174","volume":"10","author":"CJ Yang","year":"2023","unstructured":"Yang CJ, Nguyen DD, Lai JY (2023) Poly(l-histidine)-mediated on-demand therapeutic delivery of roughened ceria nanocages for treatment of chemical eye injury. Adv Sci 10(26):e2302174. https:\/\/doi.org\/10.1002\/advs.202302174","journal-title":"Adv Sci"},{"issue":"24","key":"3931_CR53","doi-asserted-by":"publisher","first-page":"25118","DOI":"10.1021\/acsnano.3c07817","volume":"17","author":"CJ Yang","year":"2023","unstructured":"Yang CJ, Anand A, Huang CC, Lai JY (2023) Unveiling the power of gabapentin-loaded nanoceria with multiple therapeutic capabilities for the treatment of dry eye disease. ACS Nano 17(24):25118\u201325135. https:\/\/doi.org\/10.1021\/acsnano.3c07817","journal-title":"ACS Nano"},{"key":"3931_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125504","volume":"675","author":"R Khadke","year":"2025","unstructured":"Khadke R, Shete A, Dashawant A (2025) Design and development of dasatinib nanoemulsions for ocular delivery: in vitro characterization, biocompatibility, and ex vivo ocular irritation study. Int J Pharm 675:125504. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125504","journal-title":"Int J Pharm"},{"issue":"1","key":"3931_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01992-2","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Chen L, Fu Y (2023) Nanotechnology-based ocular drug delivery systems: recent advances and prospects. J Nanobiotechnology 21(1):232. https:\/\/doi.org\/10.1186\/s12951-023-01992-2","journal-title":"J Nanobiotechnology"},{"key":"3931_CR56","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.2147\/DDDT.S87368","volume":"9","author":"L Zhu","year":"2015","unstructured":"Zhu L, Ao J, Li P (2015) A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: In vitro and in vivo evaluation. Drug Des Devel Ther 9:3943\u20133949. https:\/\/doi.org\/10.2147\/DDDT.S87368","journal-title":"Drug Des Devel Ther"},{"key":"3931_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2021.132409","volume":"429","author":"LJ Luo","year":"2022","unstructured":"Luo LJ, Nguyen DD, Huang CC, Lai JY (2022) Therapeutic hydrogel sheets programmed with multistage drug delivery for effective treatment of corneal abrasion. Chem Eng J 429:132409. https:\/\/doi.org\/10.1016\/j.cej.2021.132409","journal-title":"Chem Eng J"},{"key":"3931_CR58","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.foodchem.2016.11.066","volume":"221","author":"A Bannikova","year":"2017","unstructured":"Bannikova A, Evteev A, Evdokimov I (2017) Stability of omega-3 polyunsaturated fatty acids in nanoencapsulated systems. Food Chem 221:1365\u20131373. https:\/\/doi.org\/10.1016\/j.foodchem.2016.11.066","journal-title":"Food Chem"},{"issue":"7","key":"3931_CR59","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/aos.15200","volume":"102","author":"F Fineide","year":"2024","unstructured":"Fineide F, Magn\u00f8 M, Dahl\u00f8 K, Kolko M, Heegaard S, Vehof J, Utheim TP (2024) Topical glaucoma medications: possible implications on the meibomian glands. Acta Ophthalmol 102(7):735\u2013748. https:\/\/doi.org\/10.1111\/aos.15200","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"3931_CR60","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/aos.14926","volume":"100","author":"AG Skov","year":"2022","unstructured":"Skov AG, Rives AS, Freiberg J, Virgili G, Azuara-Blanco A, Kolko M (2022) Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review. Acta Ophthalmol 100(3):253\u2013261. https:\/\/doi.org\/10.1111\/aos.14926","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"3931_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/archophthalmol.2007.61","volume":"126","author":"S Rashid","year":"2008","unstructured":"Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR (2008) Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 126(2):219\u2013225. https:\/\/doi.org\/10.1001\/archophthalmol.2007.61","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"3931_CR62","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/ICO.0000000000003124","volume":"42","author":"G Giannaccare","year":"2023","unstructured":"Giannaccare G, Pellegrini M, Bernabei F, Roda M, Taroni L, Campos EC (2023) Omega-3 fatty acid supplementation for ocular surface disease in glaucoma: a systematic review and meta-analysis. Cornea 42(5):567\u2013575. https:\/\/doi.org\/10.1097\/ICO.0000000000003124","journal-title":"Cornea"},{"issue":"3","key":"3931_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17030337","volume":"17","author":"MD Chatzidaki","year":"2025","unstructured":"Chatzidaki MD, Mitsou E (2025) Advancements in nanoemulsion-based drug delivery across different administration routes. Pharmaceutics 17(3):337. https:\/\/doi.org\/10.3390\/pharmaceutics17030337","journal-title":"Pharmaceutics"},{"issue":"2","key":"3931_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/08982100600754612","volume":"16","author":"MR Mozafari","year":"2006","unstructured":"Mozafari MR, Flanagan J, Matia-Merino L, Awati A, Omri A, Suntres ZE, Singh H (2006) Recent trends in the lipid-based nanoencapsulation of antioxidants and their role in foods and pharmaceuticals. J Liposome Res 16(2):107\u2013123. https:\/\/doi.org\/10.1080\/08982100600754612","journal-title":"J Liposome Res"},{"issue":"11","key":"3931_CR65","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1039\/B922183M","volume":"39","author":"F Shahidi","year":"2010","unstructured":"Shahidi F, Zhong Y (2010) Lipid oxidation and improving the oxidative stability. Chem Soc Rev 39(11):4067\u20134079. https:\/\/doi.org\/10.1039\/B922183M","journal-title":"Chem Soc Rev"},{"issue":"3","key":"3931_CR66","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4103\/IJO.IJO_379_23","volume":"71","author":"P Rewri","year":"2023","unstructured":"Rewri P (2023) Towards better management of glaucoma in India. Indian J Ophthalmol 71(3):686\u2013688. https:\/\/doi.org\/10.4103\/IJO.IJO_379_23","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"3931_CR67","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/IJG.0b013e3181c4ac5b","volume":"19","author":"R George","year":"2010","unstructured":"George R, Ve RS, Vijaya L (2010) Glaucoma in India: estimated burden of disease. J Glaucoma 19(6):391\u2013397. https:\/\/doi.org\/10.1097\/IJG.0b013e3181c4ac5b","journal-title":"J Glaucoma"},{"issue":"2","key":"3931_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.54307\/2024.NWMJ.113","volume":"4","author":"E K\u00fc\u00e7\u00fck","year":"2024","unstructured":"K\u00fc\u00e7\u00fck E, Zor KR, \u00c7oban Karata\u015f M, Bi\u00e7er GY (2024) Prevalence of dry eye in patients using topical antiglaucoma medications. Northwest Med J 4(2):101\u2013105. https:\/\/doi.org\/10.54307\/2024.NWMJ.113","journal-title":"Northwest Med J"},{"issue":"5","key":"3931_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","volume":"3","author":"JW Brubaker","year":"2020","unstructured":"Brubaker JW, Teymoorian S, Lewis RA, Usner D, McKee HJ, Ramirez N, Kopczynski CC, Heah T (2020) One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma 3(5):327\u2013338. https:\/\/doi.org\/10.1016\/j.ogla.2020.05.008","journal-title":"Ophthalmol Glaucoma"},{"issue":"10","key":"3931_CR70","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC (2020) Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 29(10):878\u2013884. https:\/\/doi.org\/10.1097\/IJG.0000000000001634","journal-title":"J Glaucoma"},{"issue":"3","key":"3931_CR71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/bjo.2007.135111","volume":"93","author":"F Honrubia","year":"2009","unstructured":"Honrubia F, Garc\u00eda-S\u00e1nchez J, Polo V, de la Casa JM, Soto J (2009) Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 93(3):316\u2013321. https:\/\/doi.org\/10.1136\/bjo.2007.135111","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3931_CR72","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/s0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg PF, Sheu WP, XLT Study Group (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135(5):688\u2013703. https:\/\/doi.org\/10.1016\/s0002-9394(03)00098-9","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"3931_CR73","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM, Bimatoprost Study Groups 1 and 2 (2002) A one-year randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 120(10):1286\u20131293. https:\/\/doi.org\/10.1001\/archopht.120.10.1286","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"3931_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1542-0124(12)70120-9","volume":"3","author":"PA Asbell","year":"2005","unstructured":"Asbell PA, Potapova N (2005) Effects of topical antiglaucoma medications on the ocular surface. Ocul Surf 3(1):27\u201340. https:\/\/doi.org\/10.1016\/s1542-0124(12)70120-9","journal-title":"Ocul Surf"},{"issue":"3","key":"3931_CR75","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","volume":"106","author":"C Baudouin","year":"1999","unstructured":"Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, B\u00e9chetoille A (1999) Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 106(3):556\u2013563. https:\/\/doi.org\/10.1016\/S0161-6420(99)90116-1","journal-title":"Ophthalmology"},{"issue":"11","key":"3931_CR76","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grierson I, O\u2019Brien C, Hitchings RA (1994) Adverse effects of topical antiglaucoma medication: i. The conjunctival cell profile. Arch Ophthalmol 112(11):1437\u20131445. https:\/\/doi.org\/10.1001\/archopht.1994.01090230051020","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"3931_CR77","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/s0161-6420(92)31847-0","volume":"99","author":"JM Herreras","year":"1992","unstructured":"Herreras JM, Pastor JC, Calonge M, Asensio VM (1992) Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99(7):1082\u20131088. https:\/\/doi.org\/10.1016\/s0161-6420(92)31847-0","journal-title":"Ophthalmology"},{"key":"3931_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2015.07.002","volume":"94","author":"P Pandey","year":"2015","unstructured":"Pandey P, Sharma P, Waskar M, Khurana A (2015) Emerging trends in ocular drug delivery systems. Adv Drug Deliv Rev 94:2\u201315. https:\/\/doi.org\/10.1016\/j.addr.2015.07.002","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"3931_CR79","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/jps.26934","volume":"110","author":"S Swetledge","year":"2021","unstructured":"Swetledge S, Kompella UB, Mitra AK (2021) Recent developments in ocular drug delivery. J Pharm Sci 110(7):2436\u20132448. https:\/\/doi.org\/10.1002\/jps.26934","journal-title":"J Pharm Sci"},{"key":"3931_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.addr.2014.01.001","volume":"76","author":"CM Lai","year":"2014","unstructured":"Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Too L, Dong B, Constable IJ (2014) Preclinical efficacy and safety of an AAV2\/2 vector encoding pigment epithelium-derived factor for the treatment of wet age-related macular degeneration. Adv Drug Deliv Rev 76:96\u2013114. https:\/\/doi.org\/10.1016\/j.addr.2014.01.001","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"3931_CR81","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.addr.2012.09.004","volume":"65","author":"B Yavuz","year":"2013","unstructured":"Yavuz B, Bozda\u011f Pehlivan S, \u00dcnl\u00fc N (2013) An overview of ocular drug delivery. Adv Drug Deliv Rev 65(5):802\u2013813. https:\/\/doi.org\/10.1016\/j.addr.2012.09.004","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3931_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jconrel.2010.02.001","volume":"147","author":"T Gratieri","year":"2010","unstructured":"Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RFV (2010) A poloxamer\/chitosan in situ forming gel with prolonged retention time for ocular delivery. J Control Release 147(1):11\u201317. https:\/\/doi.org\/10.1016\/j.jconrel.2010.02.001","journal-title":"J Control Release"},{"issue":"7","key":"3931_CR83","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1167\/iovs.08-2826","volume":"50","author":"JB Ciolino","year":"2009","unstructured":"Ciolino JB, Stefanescu CF, Ross AE, Salvador-Culla B, Cortez P, Ford EM, Wymbs KA, Sprague SL, Cade F, Rudina SS, Kohane DS, Dohlman CH (2009) In vivo performance of a drug-eluting contact lens. Invest Ophthalmol Vis Sci 50(7):3346\u20133352. https:\/\/doi.org\/10.1167\/iovs.08-2826","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"3931_CR84","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcrs.2019.02.012","volume":"45","author":"SL Tyson","year":"2019","unstructured":"Tyson SL, Bailey R, Roman JS, Abelson M, Dhamdhere K, Kurtz RM (2019) Clinical outcomes after cataract surgery with intracanalicular dexamethasone insert. J Cataract Refract Surg 45(7):835\u2013840. https:\/\/doi.org\/10.1016\/j.jcrs.2019.02.012","journal-title":"J Cataract Refract Surg"},{"issue":"Suppl. 1","key":"3931_CR85","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/ICO.0b013e3181f9cacf","volume":"30","author":"A Higuchi","year":"2011","unstructured":"Higuchi A, Inoue H, Kanai S, Li HF, Shirakigawa N (2011) Drug delivery systems for ocular diseases. Cornea 30(Suppl. 1):S25\u2013S29. https:\/\/doi.org\/10.1097\/ICO.0b013e3181f9cacf","journal-title":"Cornea"},{"issue":"6","key":"3931_CR86","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"Haller, J. A., Bandello, F., Belfort, R., Jr., Blumenkranz, M. S., Gillies, M., Heier, J. S., Loewenstein, A., Yoon, Y. H., Jiao, J., Li, X. Y., Whitcup, S. M., & Ozurdex GENEVA Study Group","year":"2010","unstructured":"Haller, J. A., Bandello, F., Belfort, R., Jr., Blumenkranz, M. S., Gillies, M., Heier, J. S., Loewenstein, A., Yoon, Y. H., Jiao, J., Li, X. Y., Whitcup, S. M., & Ozurdex GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134-1146.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032","journal-title":"Ophthalmology"},{"issue":"8","key":"3931_CR87","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","volume":"126","author":"PA Campochiaro","year":"2019","unstructured":"Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Heier JS, RUBY Study Group (2019) Suprachoroidal triamcinolone acetonide for macular edema due to retinal vein occlusion: results of the phase 3, randomized, double-masked, controlled trials. Ophthalmology 126(8):1141\u20131154. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.036","journal-title":"Ophthalmology"},{"issue":"6","key":"3931_CR88","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000002667","volume":"40","author":"PA Campochiaro","year":"2020","unstructured":"Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Goldstein DA (2020) Suprachoroidal triamcinolone acetonide for uveitic macular edema: results of a randomized, controlled phase 3 trial. Retina 40(6):1110\u20131119. https:\/\/doi.org\/10.1097\/IAE.0000000000002667","journal-title":"Retina"},{"issue":"10097","key":"3931_CR89","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu Z-F, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Maguire AM (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial. Lancet 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-03931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-03931-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-03931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:09:42Z","timestamp":1768986582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-03931-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3931"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-03931-0","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors provide consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"64"}}